(Q36572595)

15 August 2017

1 reference

title

Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor (English)

1 reference

15 August 2017

Frank Sommer

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Drug Metabolism & Toxicology

15 August 2017

published in

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

295-301

1 reference

Sexual dysfunction in the United States: prevalence and predictors

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Sexual function in men older than 50 years of age: results from the health professionals follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Diagnosis and treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Prevention and management of erectile dysfunction following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Safety and Efficacy of Vardenafil for the Treatment of Men With Erectile Dysfunction After Radical Retropubic Prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Phosphodiesterase 5 inhibitors in male sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Mechanisms of action of PDE5 inhibition in erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Potency, selectivity, and consequences of nonselectivity of PDE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Vardenafil provides reliable efficacy over time in men with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Erectile dysfunction in the cardiac patient: how common and should we treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.2.295

21 January 2018

Identifiers

DOI

10.1517/17425255.1.2.295

1 reference

15 August 2017

1 reference